Minond Dmitriy
Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL, United States.
Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States.
Front Mol Biosci. 2020 May 6;7:75. doi: 10.3389/fmolb.2020.00075. eCollection 2020.
A disintegrin and metaproteinase 10 is an important target for multiple therapeutic areas, however, despite drug discovery efforts by both industry and academia no compounds have reached the clinic so far. The lack of enzyme and substrate selectivity of developmental drugs is believed to be a main obstacle to the success. In this review, we will focus on novel approaches and associated challenges in discovery of ADAM10 selective modulators that can overcome shortcomings of previous generations of compounds and be translated into the clinic.
解整合素金属蛋白酶10是多个治疗领域的重要靶点,然而,尽管业界和学术界都在努力进行药物研发,但迄今为止尚无化合物进入临床阶段。研发中的药物缺乏酶和底物选择性被认为是成功的主要障碍。在本综述中,我们将聚焦于发现ADAM10选择性调节剂的新方法及相关挑战,这些调节剂能够克服前代化合物的缺点并转化应用于临床。